

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/141396/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Szakmany, Tamas, Duric, Natalie, Champanerkar, Shreekant, Rimmer, Anthony and James, Christie 2021. Cytokine blockade in coronavirus disease 2019: keeping an open mind. Critical Care Explorations 3 (5) , e0424.
10.1097/CCE.0000000000000424 file

Publishers page: <http://dx.doi.org/10.1097/CCE.0000000000000424>
<<http://dx.doi.org/10.1097/CCE.0000000000000424>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Cytokine Blockade in Coronavirus Disease 2019: Keeping an Open Mind

To the Editor:

We have read the recent review on the ambiguous results of blocking the cytokine pathway published in *Critical Care Explorations* by Rizvi and Gallo De Moraes (1) with great interest. The authors made a compelling argument that blocking the single cascade of cytokine response was not successful in diverse conditions such as bacterial sepsis and acute respiratory distress syndrome (ARDS). We agree that the currently available evidence does not support the use of anticytokine therapy or cytokine removal in these settings (2). However, there is mounting evidence from both observational studies, including some published in *Critical Care Explorations*, and multicentre randomized clinical trials that interleukin (IL)-6 receptor inhibition could indeed significantly reduce mortality in a single agent caused viral sepsis, such as coronavirus disease 2019 (COVID-19) (3–6). There is significant biological plausibility for manipulating the IL-6 pathway as multiple observational studies have shown that IL-6 levels are associated with mortality and morbidity, and it was recently demonstrated that genetic variants in the IL-6 pathway are associated with life-threatening disease in critically ill COVID-19 patients (7–9). Since the publication of their review, several other well-conducted clinical trials have reported their results using tocilizumab or sarilumab in COVID-19 (6–11). By summarizing these published studies, and the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trials results from a preprint, a fixed-effects meta-analysis yields an odds ratio for mortality of 0.86 (95% CI, 0.77–0.96) for IL-6-receptor inhibition versus standard care (Fig. 1) (12). The included trials were generally at low risk of bias, and we did not detect significant heterogeneity. Among the trials with data available in the public domain, only the two largest, publicly funded studies have shown benefit.

In addition to reduction in mortality, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) trial has found significant reduction in organ support needs and reduction in length of ICU stay in the IL-6 receptor blockade arms, while the RECOVERY trial reported significantly less progression to mechanical ventilation or death in those patients who only needed supplemental oxygen on randomization (6, 12). This is especially important as these data could inform further modeling of healthcare resource needs during the pandemic, where stretched ICU capacity has been linked to adverse outcomes (13, 14).

What could be the mechanism for this significant mortality reduction, when our own data also suggest that true hyperinflammation and “cytokine storm” is a rare phenomenon in severe COVID-19 (15)? IL-6 has several diverse functions and effects, apart from being a potent proinflammatory cytokine. It has been shown to inhibit Human Leukocyte Antigen – DR isotype (HLA-DR) expression on monocytes and decrease interferon-gamma production by CD4

Tamas Szakmany, MD, PhD, FCCM^{1,2}

Natalie Duric, BA (Hons), BMBCh¹

Shreekant Champanerkar, MBBS¹

Anthony Rimmer, MBBS¹

Christie James, MRPharmS¹

Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/CCE.0000000000000424




Figure 1. Twenty-eight-day mortality risk in patients admitted to hospital with coronavirus disease 2019 and treated with interleukin (IL)-6 receptor inhibitors or usual standard care. For statistical analysis, Mantel-Haenszel (M-H) statistics with fixed-effect model was used. df = degrees of freedom, REMAP-CAP = Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia.

cells, contributing to the immune paralysis seen in sepsis (16). IL-6 receptor inhibitors may rescue the HLA-DR expression on monocytes, increase the absolute lymphocyte count and in turn increase the host's ability to produce interferon-gamma, which has significant antiviral effects (17). It is possible that the IL-6-receptor blockade is indeed not inhibiting the runaway inflammatory response in COVID-19 but that it helps to reinvigorate the normal antiviral response in a host shackled with immune paralysis.

Importantly, the trials that produced significant results recruited patients whose clinical condition was at least on the moderate to severe state on the World Health Organization scale and, in these studies, the majority of patients have received concurrent corticosteroids (6, 12). The patients in both studies had symptoms well over a week and were hospitalized for 2 days and, hence, were likely over the peak of the viral load and displaying signs of dysregulated host response (18). The median C-reactive protein levels on randomization were in the same range (130–150 mg/dL) in both studies, indicating ongoing inflammation and imbalance of the host response tilting toward persistent inflammation and immunosuppression (17, 18). These are the patients where IL-6 receptor blockade may promote restoration of normal function, rather than further dampening the proinflammatory response.

We share several of the concerns raised by the authors in their well-written review on cytokine pathway blockade in bacterial and viral sepsis. It is likely that widespread and indiscriminate use of potent immunomodulators could result in significant harm, as has been shown in previous sepsis trials that have enrolled patients with different stages of their disease. Based on our meta-analysis, it is clear that the two largest studies, which had similar inclusion criteria and were primarily performed in the same uniform healthcare setting, swing the pendulum toward benefit. Early use of IL-6 receptor blockade without concomitant steroid treatment has shown no benefit in several industry-sponsored studies conducted at the beginning of the pandemic. It is also possible that genetic heterogeneity may play a role in the efficacy of the intervention, as evidenced by the negative studies conducted in Brazil and India. We agree with the authors that there is an even greater need to understand which patient population may benefit most from these interventions. It is unclear whether, with the widespread usage of IL-6 receptor blockade (adopted in the U.K. National Health Service using the REMAP-CAP and RECOVERY study criteria), the feared increase in bacterial and fungal superinfection will manifest with worsening outcomes or frequent reinfections and rehospitalization in survivors. There is an ongoing need for well-conducted observational trials to detect any harmful signal, and

furthermore, IL-6 receptor blockade should be evaluated in more precisely described patient populations in different healthcare settings across the globe.

Beyond IL-6 receptor blockade, there are other potential ways to manipulate the inflammatory response (19). Anakinra has been used to modulate the IL-1 pathway, however, to date randomized controlled trials failed to show any significant benefit in COVID-19 (19). Notably, based on previous studies in sepsis, this intervention is likely to be successful if the patients have features of significant hyperinflammation (19). In this setting, population enrichment using multiple biomarkers is likely to lead to better results as prevalence of the hyperinflammatory phenotype of COVID-19 ARDS is a lower than initially thought (15).

Another modality, which has promise with a positive signal from a randomized controlled trial, is blocking the intracellular pathway of the janus kinase 1 (JAK1) and JAK2 signaling using baricitinib (19). The RECOVERY trial currently evaluates if adding this to the current U.K. standard of care would provide additional benefit. Combining cytokine modulation approaches could result in additional benefit; however, we agree with the authors that this could also lead to harm and should only be evaluated in clinical trials with robust safety reporting mechanisms.

Although the critical care literature is littered with negative studies in this arena, the COVID-19 pandemic is one of the first opportunities to investigate these potential therapies based on a single agent model, on the global scale. Some of the most recent results are encouraging, and we would like to highlight the need to keep an open mind, when evaluating cytokine modulation in COVID-19.

Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) trials at Aneurin Bevan University Health Board. Dr. Duric is the Associate PI for the RECOVERY trial, and Ms. James is the Associate PI for the REMAP-CAP trial at Aneurin Bevan University Health Board. The remaining authors have disclosed that they do not have any potential conflicts of interest.

REFERENCES

1. Rizvi MS, Gallo De Moraes A: New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade. *Crit Care Explor* 2021; 3:e0364
2. Rubio I, Osuchowski MF, Shankar-Hari M, et al: Current gaps in sepsis immunology: New opportunities for translational research. *Lancet Infect Dis* 2019; 19:e422–e436
3. Petrak RM, Van Hise NW, Skorodin NC, et al: Early tocilizumab dosing is associated with improved survival in critically ill patients infected with severe acute respiratory syndrome coronavirus-2. *Crit Care Explor* 2021; 3:e0395
4. Sirimatus M, Gotur DB, Patel SJ, et al: Clinical outcomes following tocilizumab administration in mechanically ventilated coronavirus disease 2019 patients. *Crit Care Explor* 2020; 2:e0232
5. Lewis TC, Adhikari S, Tatapudi V, et al: A propensity-matched cohort study of tocilizumab in patients with coronavirus disease 2019. *Crit Care Explor* 2020; 2:e0283
6. Gordon AC, Mouncey PR, Al-Beidh F, et al: The REMAP-CAP Investigators: Interleukin-6 receptor antagonists in critically ill patients with Covid-19. *N Engl J Med* 2021 Feb 25. [online ahead of print]
7. Stukas S, Hoiland RL, Cooper J, et al: The association of inflammatory cytokines in the pulmonary pathophysiology of respiratory failure in critically ill patients with coronavirus disease 2019. *Crit Care Explor* 2020; 2:e0203
8. Zhu J, Pang J, Ji P, et al: Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. *J Med Virol* 2021; 93:35–37
9. Pairo-Castineira E, Clohisey S, Klaric L, et al: Genetic mechanisms of critical illness in COVID-19. *Nature* 2021; 591:92–98
10. Soin AS, Kumar K, Choudhary NS, et al: Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): An open-label, multicentre, randomised, controlled, phase 3 trial. *Lancet Respir Med* 2021 Mar 4. [online ahead of print]
11. Lescure F-X, Honda H, Fowler RA, et al: Sarilumab COVID-19 Global Study Group: Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2021 Mar 4. [online ahead of print]
12. Horby PW, Pessoa-Amorim G, Peto L, et al: RECOVERY Collaborators Group: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a

1 Critical Care Directorate, Aneurin Bevan University Health Board, Newport, United Kingdom

2 Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff, United Kingdom

All authors contributed to the study conception, design, material preparation, data collection, and analysis. The first draft of the article was written by Dr. Szakmany, and all authors commented on previous versions of the article. All authors read and approved the final article.

Dr. Szakmany is the Associate Editor for Social Media at Critical Care Explorations and the local Principal Investigator (PI) for the Randomised Evaluation of COVID-19 Therapy (RECOVERY) and

- randomised, controlled, open-label, platform trial. *medRxiv* 2021.02.11.21249258
13. Williams E, Szakmany T, Spernaes I, et al: Discrete-event simulation modeling of critical care flow: New hospital, old challenges. *Crit Care Explor* 2020; 2:e0174
 14. Tandon P, Leibner E, Ahmed S, et al: Comparing seasonal trends in coronavirus disease 2019 patient data at a quaternary hospital in New York City. *Crit Care Explor* 2021; 3:e0381
 15. Sinha P, Calfee CS, Cherian S, et al: Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: A prospective observational study. *Lancet Respir Med* 2020; 8:1209–1218
 16. Ohno Y, Kitamura H, Takahashi N, et al: IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells. *Cancer Immunol Immunother* 2016; 65:193–204
 17. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al: Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host Microbe* 2020; 27:992–1000.e3
 18. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al: Imbalanced host response to SARS-CoV-2 drives development of COVID-19. *Cell* 2020; 181:1036–1045.e9
 19. Nissen CB, Sciascia S, de Andrade D, et al: The role of anti-rheumatics in patients with COVID-19. *Lancet Rheumatol* 2021 Mar 30. [online ahead of print]